Narcolepsy - Pipeline Review, H2 2020

October 2020 | 100 pages | ID: NBDC4023D02EN
Global Markets Direct

Abstracts

Narcolepsy - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2020, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.
Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 5, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Narcolepsy - Overview
Narcolepsy - Therapeutics Development
Narcolepsy - Therapeutics Assessment
Narcolepsy - Companies Involved in Therapeutics Development
Narcolepsy - Drug Profiles
Narcolepsy - Dormant Projects
Narcolepsy - Discontinued Products
Narcolepsy - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Narcolepsy, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Narcolepsy - Pipeline by Avadel Pharmaceuticals Plc, H2 2020
Narcolepsy - Pipeline by Axsome Therapeutics Inc, H2 2020
Narcolepsy - Pipeline by Balance Therapeutics Inc, H2 2020
Narcolepsy - Pipeline by Bioprojet SCR, H2 2020
Narcolepsy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
Narcolepsy - Pipeline by Inexia Ltd, H2 2020
Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H2 2020
Narcolepsy - Pipeline by NLS Pharma Group, H2 2020
Narcolepsy - Pipeline by Ono Pharmaceutical Co Ltd, H2 2020
Narcolepsy - Pipeline by Orexia Ltd, H2 2020
Narcolepsy - Pipeline by Seelos Therapeutics, Inc., H2 2020
Narcolepsy - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2020
Narcolepsy - Pipeline by Suven Life Sciences Ltd, H2 2020
Narcolepsy - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
Narcolepsy - Pipeline by Theranexus SAS, H2 2020
Narcolepsy - Pipeline by Vallon Pharmaceuticals Inc, H2 2020
Narcolepsy - Pipeline by XWPharma, H2 2020
Narcolepsy - Dormant Projects, H2 2020
Narcolepsy - Dormant Projects, H2 2020 (Contd..1), H2 2020
Narcolepsy - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Narcolepsy, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020